2865 N. Reynolds Road
About VentureMed GroupVentureMed Group, Inc. is a commercial-stage medical device company that develops and markets cost-effective interventional devices to improve the treatment of peripheral artery disease. The Company's innovative product platforms are designed to improve clinical outcomes and reduce procedural costs.
CEO: Gary L. Smith
CSO: John P. Pigott
COO and CFO: Brent Cousino
5 articles with VentureMed Group
FLEX Vessel Prep™ System Data Presented at New Cardiovascular Horizons Conference Shows Key Findings including Luminal Gain
VentureMed Group, Inc., a privately-held medical device innovator in vessel preparation for interventional treatment of peripheral arterial disease and stenoses of arteriovenous fistulas and grafts, announced new data presented at the 20th Annual New Cardiovascular Horizons Annual Conference, May 29-31, in New Orleans, Louisiana.
Company will be relocating from its current facilities in the ProMedica Innovations Center in Toledo, Ohio to Minneapolis, Minnesota as the Company continues to develop and grow.
Actively enrolling up to 150 patients to evaluate lumen patency at one year obtained by arterial vessel preparation with the FLEX Vessel Preparation System prior to conventional endovascular recanalization of the superficial femoral artery (SFA) and popliteal artery (PA).
VentureMed Group, Inc. announced initial enrollment in a new non-randomized, single-site, prospective study to evaluate the safety and efficacy of the FLEX Scoring Catheter with a Drug Coated Balloon (DCB) balloon in the maintenance of arteriovenous access sites.